Skip to main navigation
Skip to search
Skip to main content
University of East Anglia Home
Home
People
Organisations
Research output
Projects
Datasets
Equipment
Prizes
Activities
Press/Media
Impacts
Search by expertise, name or affiliation
Developing a new targeted therapy for hormone-refractory prostate cancer: preclinical validation of everolimus-docetaxel containing nanoparticles.
Cooper, Colin
(Principal Investigator)
Pshezhetskiy, Dmitry
(Co-Investigator)
Wang, Qi
(Researcher)
Norwich Medical School
Cancer Studies
Metabolic Health
Overview
Project Details
Status
Finished
Effective start/end date
16/09/16
→
15/04/17
Funding
Norfolk & Norwich University Hospitals NHS Foundation Trust:
£26,341.62
View all
View less